Compare Boston Scientific Corporation (BSX) vs Newegg Commerce Inc (NEGG) Price & Performance

Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.

BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.

NEGG trades at $13.87, down 1.98% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $4.88 million for 2025, though revenue improved to $1.44 billion. Recent news highlights AI shopping initiatives and the FantasTech sale, indicating ongoing business development efforts. Cash flow from operations remains negative at -$26.97 million, but financing activities provided a net cash inflow of $8.91 million.

The outlook is mixed; a single analyst rates NEGG a buy, and profitability may recover by 2026. However, persistent operating losses, weak cash generation, and high debt-to-asset ratios pose significant risks. Investors should weigh potential e-commerce growth against fundamental weaknesses and market volatility.